1. Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis
- Author
-
Andrew J. Lucke, Robert Reid, Soo-Hyun Kim, Lap Hing Chi, Robin L. Anderson, Delphine Denoyer, Ana Carolina Baptista Moreno Martin, David P. Fairlie, Xiawei Ling, Normand Pouliot, and Richard P. Redvers
- Subjects
0301 basic medicine ,Mammary gland ,Medicine (miscellaneous) ,lcsh:Medicine ,Radiation Tolerance ,Metastasis ,Transcriptome ,Mice ,Breast cancer ,0302 clinical medicine ,Immunology and Microbiology (miscellaneous) ,Cell Movement ,Uncategorized ,0303 health sciences ,Brain Neoplasms ,Histone deacetylase inhibitor ,3. Good health ,Phenotype ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,lcsh:RB1-214 ,Signal Transduction ,Research Article ,medicine.drug_class ,Neuroscience (miscellaneous) ,Breast Neoplasms ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,In vivo ,Cell Line, Tumor ,4T1Br4 ,lcsh:Pathology ,Cell Adhesion ,medicine ,Animals ,Humans ,Neoplasm Invasiveness ,030304 developmental biology ,business.industry ,Brain metastasis ,lcsh:R ,medicine.disease ,Histone Deacetylase Inhibitors ,Gene expression profiling ,030104 developmental biology ,Syngeneic mouse model ,Cancer research ,Histone deacetylase ,business ,Genes, Neoplasm - Abstract
Breast cancer brain metastases remain largely incurable. Although several mouse models have been developed to investigate the genes and mechanisms regulating breast cancer brain metastasis, these models often lack clinical relevance since they require the use of immunocompromised mice and/or are poorly metastatic to brain from the mammary gland. We describe the development and characterisation of an aggressive brain metastatic variant of the 4T1 syngeneic model (4T1Br4) that spontaneously metastasises to multiple organs, but is selectively more metastatic to the brain from the mammary gland than parental 4T1 tumours. As seen by immunohistochemistry, 4T1Br4 tumours and brain metastases display a triple-negative phenotype, consistent with the high propensity of this breast cancer subtype to spread to brain. In vitro assays indicate that 4T1Br4 cells have an enhanced ability to adhere to or migrate across a brain-derived endothelial monolayer and greater invasive response to brain-derived soluble factors compared to 4T1 cells. These properties are likely to contribute to the brain selectivity of 4T1Br4 tumours. Expression profiling and gene set enrichment analyses demonstrate the clinical relevance of the 4T1Br4 model at the transcriptomic level. Pathway analyses implicate tumour-intrinsic immune regulation and vascular interactions in successful brain colonisation, revealing potential therapeutic targets. Evaluation of two histone deacetylase inhibitors, SB939 and 1179.4b, shows partial efficacy against 4T1Br4 metastasis to brain and other sites in vivo, and potent radio-sensitising properties in vitro. The 4T1Br4 model provides a clinically relevant tool for mechanistic studies and to evaluate novel therapies against brain metastasis. This article has an associated First Person interview with Soo-Hyun Kim, joint first author of the paper., Summary: The authors introduce a new syngeneic mouse model of spontaneous breast cancer brain metastasis, demonstrate its phenotypic, functional and transcriptomic relevance to human TNBC brain metastasis, and test novel therapies.
- Published
- 2023
- Full Text
- View/download PDF